NCT04180579Active, not recruiting
Safety of Lower Scalp Cooling Temperature to Prevent Hair Loss From Chemotherapy in Breast Cancer Patients
Safety and Tolerability of Lower Scalp Cooling Temperatures to Prevent Doxorubicin Plus Cyclophosphamide and Paclitaxel-induced Alopecia in Breast Cancer Patients
In the register
This trial is not attached to a programme in the register yet. Unattached trials are kept on purpose: they are where new programmes turn up first.
What the registry records
- Status
- Active, not recruiting
- Declared phase
- Not applicable (NA in the registry)
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Participants (registry)
- 34
- Start
- November 2019
- Primary completion
- May 2027 (planned)
- Study completion
- May 2027 (planned)
- Last registry update
- June 2026
- Countries
- United States
Conditions studied: Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
Interventions: PAXMAN Scalp Cooler
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.